You are conducting a study comparing the efficacy of two different statin medications. Two groups are placed on different statin medications, statin A and statin B. Baseline LDL levels are drawn for each group and are subsequently measured every 3 months for 1 year. Average baseline LDL levels for each group were identical. The group receiving statin A exhibited an 11 mg/dL greater reduction in LDL in comparison to the statin B group. Your statistical analysis reports a p-value of 0.052. Which of the following best describes the meaning of this p-value?

There is a 5.2% chance of observing a difference in reduction of LDL of 11 mg/dL or greater even if the two medications have identical effects

There is a 95% chance that the difference in reduction of LDL observed reflects a real difference between the two groups

Though A is more effective than B, there is a 5% chance the difference in reduction of LDL between the two groups is due to chance

If 100 permutations of this experiment were conducted, 5 of them would show similar results to those described above

This is a statistically significant result

A 28-year-old male presents to his primary care physician with complaints of intermittent abdominal pain and alternating bouts of constipation and diarrhea. His medical chart is not significant for any past medical problems or prior surgeries. He is not prescribed any current medications. Which of the following questions would be the most useful next question in eliciting further history from this patient?

"Can you tell me more about the symptoms you have been experiencing?"

"Does the diarrhea typically precede the constipation, or vice-versa?"

"Is the diarrhea foul-smelling?"

"Please rate your abdominal pain on a scale of 1-10, with 10 being the worst pain of your life"

"Are the symptoms worse in the morning or at night?"

A pharmaceutical company reports a new antihypertensive drug reduces cardiovascular events with an NNT of 50 over 5 years based on a trial of 10,000 patients. An independent analysis reveals the benefit was driven entirely by a subgroup with resistant hypertension (20% of participants, NNT=15), while the remaining 80% showed no benefit over standard therapy (NNT approaching infinity). Evaluate the ethical and regulatory implications of reporting the overall NNT.

The overall NNT is misleading; approval should be restricted to resistant hypertension population where benefit is demonstrated

Conduct a new trial in the general hypertensive population to validate efficacy before broader approval

The subgroup analysis represents data dredging; only the overall NNT should be used for clinical decisions

The overall NNT of 50 is statistically valid and appropriate for regulatory approval and marketing

Report both overall and subgroup NNTs; allow clinicians to determine appropriate use based on patient characteristics

Reporting in clinical guidelines for USMLE Step 2 CK: High-Yield Biostatistics Lessons

NNT/NNH - The Core Numbers Game

NNT (Number Needed to Treat): Number of patients to treat to prevent 1 additional bad outcome.
- Formula: $NNT = 1 / ARR$ (Absolute Risk Reduction)
- Lower NNT = more effective treatment. An ideal NNT is 1.
NNH (Number Needed to Harm): Number of patients to expose to a risk factor to cause 1 additional bad outcome.
- Formula: $NNH = 1 / ARI$ (Absolute Risk Increase)
- Higher NNH = safer exposure.

2x2 Table for NNT Calculation

⭐ Always calculate NNT/NNH from absolute risk changes, not relative risk. A common exam trap is to provide relative risk data, requiring you to first calculate the absolute risks.

NNT Interpretation - Context is Everything

NNT is not a fixed value; its clinical meaning depends on context.
Key Factors for Judgment:
- Baseline Risk: Higher patient risk (↑ ARR) = lower (better) NNT. Formula: $NNT = 1 / ARR$.
- Outcome Severity: A high NNT is more acceptable for preventing death than for a minor side effect.
- Harm (NNH): Weigh NNT against the Number Needed to Harm. Ideal drugs: low NNT, high NNH.
- Timeframe: NNT is only valid for the study's duration.

⭐ A treatment is justified when NNT is much lower than NNH. If NNT is close to or exceeds NNH, the harm may outweigh the benefit.

NNT vs NNH for ASCVD events prevented by statins

Guideline Reporting - The CONSORT Connection

CONSORT 2010 Flow Diagram for Clinical Trial Reporting

CONSORT (Consolidated Standards of Reporting Trials): An evidence-based framework ensuring transparent and complete reporting of Randomized Controlled Trials (RCTs).
- Crucial for readers to critically appraise a study's validity before accepting its conclusions or calculating metrics like NNT.
Core Mandates:
- Flow Diagram: Tracks participants from enrollment through analysis, highlighting dropouts (loss to follow-up). Essential for assessing attrition bias.
- 25-Item Checklist: Specifies minimum reporting criteria for each section of the trial manuscript, promoting methodological clarity.

⭐ The CONSORT flow diagram is critical for assessing attrition bias (loss to follow-up). High or differential attrition can render NNT/NNH calculations misleading, as it may violate the intention-to-treat (ITT) principle.

High‑Yield Points - ⚡ Biggest Takeaways

NNT (Number Needed to Treat) is the number of patients needing treatment to prevent one adverse outcome; a lower NNT is better.

NNH (Number Needed to Harm) is the number exposed to a risk factor to cause one adverse outcome; a higher NNH is safer.

Calculated as the inverse of risk change: NNT = 1/ARR and NNH = 1/ARI.

Guidelines use NNT/NNH to weigh the benefits vs. risks of an intervention.

A favorable therapy has a low NNT and a high NNH.

Confidence intervals for NNT/NNH that include infinity are not statistically significant.

Continue reading on Oncourse

CONTINUE READING — FREE

or get the app

App Store|Google Play